245 related articles for article (PubMed ID: 6187879)
1. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.
Uyttenhove C; Maryanski J; Boon T
J Exp Med; 1983 Mar; 157(3):1040-52. PubMed ID: 6187879
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants.
Maryanski JL; Marchand M; Uyttenhove C; Boon T
Int J Cancer; 1983 Jan; 31(1):119-23. PubMed ID: 6187698
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response.
Maryanski JL; Van Snick J; Cerottini JC; Boon T
Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607
[TBL] [Abstract][Full Text] [Related]
5. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
6. Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.
Levraud JP; Pannetier C; Langlade-Demoyen P; Brichard V; Kourilsky P
J Exp Med; 1996 Feb; 183(2):439-49. PubMed ID: 8627157
[TBL] [Abstract][Full Text] [Related]
7. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
Carayanniotis G; Halloran PF
Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice.
Uyttenhove C; Van Snick J; Boon T
J Exp Med; 1980 Nov; 152(5):1175-83. PubMed ID: 6776226
[TBL] [Abstract][Full Text] [Related]
9. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids.
Maryanski JL; Szpirer J; Szpirer C; Boon T
Somatic Cell Genet; 1983 May; 9(3):345-57. PubMed ID: 6407125
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.
Boon T; Van Snick J; Van Pel A; Uyttenhove C; Marchand M
J Exp Med; 1980 Nov; 152(5):1184-93. PubMed ID: 6776227
[TBL] [Abstract][Full Text] [Related]
11. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.
Lethé B; van den Eynde B; van Pel A; Corradin G; Boon T
Eur J Immunol; 1992 Sep; 22(9):2283-8. PubMed ID: 1381312
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
[TBL] [Abstract][Full Text] [Related]
13. Targeting an anti-viral CD8+ T cell response to a growing tumor facilitates its rejection.
Böhm W; Schirmbeck R; Reimann J
Cancer Immunol Immunother; 1997 Jun; 44(4):230-8. PubMed ID: 9222282
[TBL] [Abstract][Full Text] [Related]
14. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815.
Brichard VG; Warnier G; Van Pel A; Morlighem G; Lucas S; Boon T
Eur J Immunol; 1995 Mar; 25(3):664-71. PubMed ID: 7705394
[TBL] [Abstract][Full Text] [Related]
15. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.
Bilsborough J; Van Pel A; Uyttenhove C; Boon T; Van den Eynde BJ
J Immunol; 1999 Mar; 162(6):3534-40. PubMed ID: 10092811
[TBL] [Abstract][Full Text] [Related]
16. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
17. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
Prell RA; Kerkvliet NI
J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens.
Van Snick J; Maryanski J; Van Pel A; Parmiani G; Boon T
Eur J Immunol; 1982 Nov; 12(11):905-8. PubMed ID: 6818041
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay.
Wölfel T; Van Pel A; De Plaen E; Lurquin C; Maryanski JL; Boon T
Immunogenetics; 1987; 26(3):178-87. PubMed ID: 3114137
[TBL] [Abstract][Full Text] [Related]
20. Production of tumor-specific suppressor T cell hybridomas.
Bear HD
J Surg Res; 1987 Apr; 42(4):369-76. PubMed ID: 2437390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
